News Headlines

  1. Neurimmune Expands Collaboration With AstraZeneca To Develop And Commercialize Fibril Depleter NI009 For AL Amyloidosis 12/4/2025

    Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis.

  2. mAbxience And HP Drive The Use Of Artificial Intelligence In Biomanufacturing And Biosimilar Development 12/4/2025

    mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars.

  3. Eckert & Ziegler And SK Biopharmaceuticals Sign Actinium-225 Supply Agreement 12/3/2025

    Eckert & Ziegler has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in South Korea.

  4. Luxna Deepens Collaboration With BioSpring To Advance Therapeutic Oligonucleotide Development 12/2/2025

    Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato; Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) and one of the largest contract development and manufacturing organizations (CDMO) specializing in oligonucleotide therapeutics, BioSpring GmbH (CEO: Dr. Sylvia Wojczewski; Headquarters: Frankfurt am Main, Germany, hereinafter “BioSpring”) announced a new collaboration.

  5. BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500M Equity Facility From ARC Group International To Support Expansion Of Precision Diagnostics, CDMO Operations, And Therapeutic Commercialization 12/2/2025

    BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the “Facility”) with ARC Group International Ltd. (“ARC”), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer.

  6. Rentschler Biopharma And Coriolis Pharma Announce Strategic Collaboration For Integrated Biopharma Solutions 12/2/2025

    Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

  7. WuXi Biologics Extends Global CRDMO Network To Qatar Through Strategic MoU Signed With Qatar Free Zones Authority 12/2/2025

    WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East.

  8. Cellipont Bioservices Expands Manufacturing Capabilities With New Ballroom-Style Cleanroom And 50-Liter Single-Use Bioreactor To Advance Cell Therapy Production 12/2/2025

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the completion of its ballroom-style cleanroom, featuring a state-of-the-art 50-liter single-use bioreactor. This facility expansion marks a major milestone in Cellipont's continued investment to meet the growing demand for advanced manufacturing of exosome, induced pluripotent stem cell (iPSC), and mesenchymal stem cell (MSC) therapies.

  9. Thermo Fisher Scientific Deepens Investment In Asia's Biopharma Ecosystem With Expansion Of Bioprocess Design Centers 12/2/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry.

  10. AGC Biologics Partners With ATUM To Accelerate Timelines For Cell Line Development 12/2/2025

    As drug developers face increasing pressure to lower prices and accelerate time to market, global biopharmaceutical contract development and manufacturing organization AGC Biologics is expanding its Cell Line Development Center of Excellence by partnering with ATUM to integrate the Leap-In Transposase expression platform within its offerings.